Overcoming the pulmonary barrier: New insights to improve the efficiency of inhaled therapeutics

European Journal of Nanomedicine

Volumn 6, Issue 3, 2014, Pages 157-169

  Murgia, Xabi ^a   De Souza Carvalho, Cristiane ^a   Lehr, Claus Michael ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

mucus; nanoparticles; pulmonary barriers; respiratory epithelium; surfactant

Indexed keywords

AEROSOLS; BIOCOMPATIBILITY; BIOLOGICAL ORGANS; CONTROLLED DRUG DELIVERY; DEPOSITS; EFFICIENCY; FUNCTIONAL POLYMERS; MACHINERY; NANOPARTICLES; PARTICLES (PARTICULATE MATTER); PHOSPHOLIPIDS; SURFACE ACTIVE AGENTS;

DRUG-METABOLIZING ENZYMES; INNOVATIVE STRATEGIES; MICRO AND NANO-PARTICLE; MUCUS; PULMONARY BARRIERS; PULMONARY SURFACTANTS; RESPIRATORY EPITHELIUMS; THERAPEUTIC EFFICIENCY;

TARGETED DRUG DELIVERY;

CHITOSAN; DRUG CARRIER; LUNG SURFACTANT; MUCIN; MUCOLYTIC AGENT; NANOPARTICLE; POLYVINYL ALCOHOL;

AEROSOL; COATED PARTICLE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; ENDOTHELIUM CELL; HUMAN; IMMUNE RESPONSE; INHALATION; INHALER; LUNG ALVEOLUS CELL; LUNG ALVEOLUS EPITHELIUM; LUNG ALVEOLUS MACROPHAGE; LUNG GAS EXCHANGE; MICROENVIRONMENT; MOLECULAR WEIGHT; MUCOCILIARY CLEARANCE; MUCUS; PARTICLE SIZE; PATHOGENESIS; PERMEABILITY BARRIER; PHAGOCYTOSIS; PINOCYTOSIS; POLLUTANT; POLYMERIZATION; PULMONARY BARRIER; RESPIRATORY EPITHELIUM; REVIEW; STATIC ELECTRICITY; SURFACE TENSION; THERAPY EFFECT; UPPER RESPIRATORY TRACT;

EID: 84907558987     PISSN: 16625986     EISSN: 1662596X     Source Type: Journal    
DOI: 10.1515/ejnm-2014-0019     Document Type: Review

References (88)

1. Wright BM. A new nebuliser. Lancet 1958;2:24-5.
2. Dolovich MB, Dhand R. Aerosol drug delivery: developments in device design and clinical use. Lancet 2011;377:1032-45.
3. Paranjpe M, Muller-Goymann CC. Nanoparticle-mediated pulmonary drug delivery: A review. Int J Mol Sci 2014;15:5852-73.
4. Mahmud A, Discher DE. Lung vascular targeting through inhalation delivery: insight from filamentous viruses and other shapes. IUBMB Life 2011;63:607-12.
5. Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov 2007;6:67-74.
6. OCallaghan C, Barry PW. The science of nebulised drug delivery. Thorax. 1997;52(Suppl 2):S31-44.
7. Patton JS, Fishburn CS, Weers JG. The lungs as a portal of entry for systemic drug delivery. Proc Am Thorac Soc 2004;1:338-44.
8. Rubin BK. Pediatric aerosol therapy: new devices and new drugs. Respir Care 2011;56:1411-21; discussion 21-3.
9. Frijlink HW, De Boer AH. Dry powder inhalers for pulmonary drug delivery. Expert Opin Drug Deliv 2004;1:67-86.
10. Quattrin T, Belanger A, Bohannon NJ, Schwartz SL, Exubera Phase IIISG. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 2004;27:2622-7.
11. Neumiller JJ, Campbell RK, Wood LD. A review of inhaled technosphere insulin. Ann Pharmacother 2010;44:1231-9.
12. Brand P, Schulte M, Wencker M, Herpich CH, Klein G, Hanna K, et al. Lung deposition of inhaled alpha1-proteinase inhibitor in cystic fibrosis and alpha1-Antitrypsin deficiency. Eur Respir J 2009;34:354-60.
13. Newman SP, Pavia D, Moren F, Sheahan NF, Clarke SW. Deposition of pressurised aerosols in the human respiratory tract. Thorax 1981;36:52-5.
14. Patton JS, Brain JD, Davies LA, Fiegel J, Gumbleton M, Kim KJ, et al. The particle has landed-characterizing the fate of inhaled pharmaceuticals. J Aerosol Med Pulm Drug Deliv 2010;23 (Suppl 2):S71-87.
15. Knowles MR, Boucher RC. Mucus clearance as a primary innate defense mechanism for mammalian airways. J Clin Invest 2002;109:571-7.
16. Ruge CA, Kirch J, Canadas O, Schneider M, Perez-Gil J, Schaefer UF, et al. Uptake of nanoparticles by alveolar macrophages is triggered by surfactant protein A. Nanomedicine 2011;7:690-3.
17. Lai SK, Wang YY, Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev 2009;61:158-71.
18. Sung JC, Pulliam BL, Edwards DA. Nanoparticles for drug delivery to the lungs. Trends Biotechnol 2007;25:563-70.
19. Herd H, Daum N, Jones AT, Huwer H, Ghandehari H, Lehr CM. Nanoparticle geometry and surface orientation influence mode of cellular uptake. ACS Nano 2013;7:1961-73.
20. Mura S, Hillaireau H, Nicolas J, Kerdine-Romer S, Le Droumaguet B, Delomenie C, et al. Biodegradable nanoparticles meet the bronchial airway barrier: how surface properties affect their interaction with mucus and epithelial cells. Biomacromolecules 2011;12:4136-43.
21. Verma NK, Crosbie-Staunton K, Satti A, Gallagher S, Ryan KB, Doody T, et al. Magnetic core-shell nanoparticles for drug delivery by nebulization. J Nanobiotechnology 2013;11:1.
22. Leff AR, Schumacker PT. Respiratory physiology: basics and applications. Philadephia: W.B. Saunders Co.; 1993. 198 pp.
23. Muller L, Riediker M, Wick P, Mohr M, Gehr P, Rothen-Rutishauser B. Oxidative stress and inflammation response after nanoparticle exposure: differences between human lung cell monocultures and an advanced three-dimensional model of the human epithelial airways. J R Soc Interface 2010;7 (Suppl 1):S27-40.
24. Bur M, Lehr CM. Pulmonary cell culture models to study the safety and efficacy of innovative aerosol medicines. Expert Opin Drug Deliv 2008;5:641-52.
25. Steimer A, Haltner E, Lehr CM. Cell culture models of the respiratory tract relevant to pulmonary drug delivery. J Aerosol Med 2005;18:137-82.
26. Inayama Y, Hook GE, Brody AR, Cameron GS, Jetten AM, Gilmore LB, et al. The differentiation potential of tracheal basal cells. Lab Invest 1988;58:706-17.
27. Florea BI, Cassara ML, Junginger HE, Borchard G. Drug transport and metabolism characteristics of the human airway epithelial cell line Calu-3. J Control Release 2003;87:131-8.
28. Sanders N, Rudolph C, Braeckmans K, De Smedt SC, Demeester J. Extracellular barriers in respiratory gene therapy. Adv Drug Deliv Rev 2009;61:115-27.
29. Patton, JS. Mechanisms of macromolecule absorption by the lungs. Adv. Drug Deliv. Rev. 1996;1919:3-36.
30. Salomon JJ, Muchitsch VE, Gausterer JC, Schwagerus E, Huwer H, Daum N, et al. The Cell Line NCl-H441 Is a Useful in Vitro Model for Transport Studies of Human Distal Lung Epithelial Barrier. Mol Pharm 2014;11:995-1006.
31. Stone KC, Mercer RR, Gehr P, Stockstill B, Crapo JD. Allometric relationships of cell numbers and size in the mammalian lung. Am J Respir Cell Mol Biol 1992;6:235-43.
32. Creuwels LA, van Golde LM, Haagsman HP. The pulmonary surfactant system: biochemical and clinical aspects. Lung 1997;175:1-39.
33. Orgeig S, Bernhard W, Biswas SC, Daniels CB, Hall SB, Hetz SK, et al. The anatomy, physics, and physiology of gas exchange surfaces: is there a universal function for pulmonary surfactant in animal respiratory structures? Integr Comp Biol 2007;47:610-27.
34. Lopez-Rodriguez E, Perez-Gil J. Structure-function relationships in pulmonary surfactant membranes: From biophysics to therapy. Biochim Biophys Acta 2014;1838:1568-85.
35. Pastva AM, Wright JR, Williams KL. Immunomodulatory roles of surfactant proteins A and D: implications in lung disease. Proc Am Thorac Soc 2007;4:252-7.
36. Geiser M. Update on macrophage clearance of inhaled micro-And nanoparticles. J Aerosol Med Pulm Drug Deliv 2010;23:207-17.
37. Kirby AC, Coles MC, Kaye PM. Alveolar macrophages transport pathogens to lung draining lymph nodes. J Immunol 2009;183:1983-9.
38. Wright JR. Clearance and recycling of pulmonary surfactant. Am J Physiol 1990;259:L1-12.
39. Hiller FC. Therapeutic Aerosols: An Overview from a Clinical Perspective. In: Hickey AJ, editor. Pharmaceutical Inhalation Aerosol Technology. 2nd ed. New York: M. Dekker; 2004. p. 423-57.
40. Bastacky J, Lee CY, Goerke J, Koushafar H, Yager D, Kenaga L, et al. Alveolar lining layer is thin and continuous: low-temperature scanning electron microscopy of rat lung. J Appl Physiol (1985) 1995;79:1615-28.
41. Dobbs LG. Isolation and culture of alveolar type II cells. Am J Physiol 1990;258:L134-47.
42. Frank JA. Claudins and alveolar epithelial barrier function in the lung. Ann N Y Acad Sci 2012;1257:175-83.
43. Geiser M, Rothen-Rutishauser B, Kapp N, Schurch S, Kreyling W, Schulz H, et al. Ultrafine particles cross cellular membranes by nonphagocytic mechanisms in lungs and in cultured cells. Environ Health Perspect 2005;113:1555-60.
44. Kirch JR, Ruge CA, Schneider C, Hanes J, Lehr CM. Nanostructures for overcoming the pulmonary barriers: physiological considerations and mechanistic issues. Nanostructured Biomaterials for Overcoming Biological Barriers: Royal Society of Chemistry; 2012. p. 239-71.
45. Ruge CA, Schaefer UF, Herrmann J, Kirch J, Canadas O, Echaide M, et al. The interplay of lung surfactant proteins and lipids assimilates the macrophage clearance of nanoparticles. PLoS One. 2012;7:e40775.
46. Shoyele SA, Cawthorne S. Particle engineering techniques for inhaled biopharmaceuticals. Adv Drug Deliv Rev 2006;58:1009-29.
47. Roberts RA, Shen T, Allen IC, Hasan W, DeSimone JM, Ting JP. Analysis of the murine immune response to pulmonary delivery of precisely fabricated nano-And microscale particles. PLoS One 2013;8:e62115.
48. Nicod LP. Lung defences: An overview. Eur Respir Rev. 2005;14:5.
49. Stewart CE, Torr EE, Mohd Jamili NH, Bosquillon C, Sayers I. Evaluation of differentiated human bronchial epithelial cell culture systems for asthma research. J Allergy (Cairo) 2012;2012:943982.
50. Ma CC, Ma S. The role of surfactant in respiratory distress syndrome. Open Respir Med J 2012;6:44-53.
51. Blanco O, Perez-Gil J. Biochemical and pharmacological differences between preparations of exogenous natural surfactant used to treat Respiratory Distress Syndrome: role of the different components in an efficient pulmonary surfactant. Eur J Pharmacol 2007;568:1-15.
52. Veldhuizen R, Nag K, Orgeig S, Possmayer F. The role of lipids in pulmonary surfactant. Biochim Biophys Acta 1998;1408:90-108.
53. Schurch D, Ospina OL, Cruz A, Perez-Gil J. Combined and independent action of proteins SP-B and SP-C in the surface behavior and mechanical stability of pulmonary surfactant films. Biophys J 2010;99:3290-9.
54. Johansson J, Curstedt T. Molecular structures and interactions of pulmonary surfactant components. Eur J Biochem 1997;244:675-93.
55. Haagsman HP, Diemel RV. Surfactant-Associated proteins: functions and structural variation. Comp Biochem Physiol A Mol Integr Physiol 2001;129:91-108.
56. Perez-Gil J, Weaver TE. Pulmonary surfactant pathophysiology: current models and open questions. Physiology (Bethesda) 2010;25:132-41.
57. Balakrishnan A, Rege BD, Amidon GL, Polli JE. Surfactant-mediated dissolution: contributions of solubility enhancement and relatively low micelle diffusivity. J Pharm Sci 2004;93:2064-75.
58. Kirch J, Guenther M, Doshi N, Schaefer UF, Schneider M, Mitragotri S, et al. Mucociliary clearance of micro-And nanoparticles is independent of size, shape and charge-An ex vivo and in silico approach. J Control Release 2012;159:128-34.
59. Schurch S, Gehr P, Im Hof V, Geiser M, Green F. Surfactant displaces particles toward the epithelium in airways and alveoli. Respir Physiol 1990;80:17-32.
60. Lynch I, Salvati A, Dawson KA. Protein-nanoparticle interactions: what does the cell see? Nat Nanotechnol 2009;4:546-7.
61. Beck-Broichsitter M, Ruppert C, Schmehl T, Gunther A, Seeger W. Biophysical inhibition of synthetic vs. naturally-derived pulmonary surfactant preparations by polymeric nanoparticles. Biochim Biophys Acta 2014;1838:474-81.
62. Haghi M, Young PM, Traini D, Jaiswal R, Gong J, Bebawy M. Time-And passage-dependent characteristics of a Calu-3 respiratory epithelial cell model. Drug Dev Ind Pharm 2010;36:1207-14.
63. Randell SH, Boucher RC, University of North Carolina Virtual Lung G. Effective mucus clearance is essential for respiratory health. Am J Respir Cell Mol Biol 2006;35:20-8.
64. Gumbiner BM. Breaking through the tight junction barrier. J Cell Biol 1993;123:1631-3.
65. Pohl C, Hermanns MI, Uboldi C, Bock M, Fuchs S, Dei-Anang J, et al. Barrier functions and paracellular integrity in human cell culture models of the proximal respiratory unit. Eur J Pharm Biopharm 2009;72:339-49.
66. Mathia NR, Timoszyk J, Stetsko PI, Megill JR, Smith RL, Wall DA. Permeability characteristics of calu-3 human bronchial epithelial cells: in vitro-in vivo correlation to predict lung absorption in rats. J Drug Target 2002;10:31-40.
67. Borchard G, Cassara ML, Roemele PE, Florea BI, Junginger HE. Transport and local metabolism of budesonide and fluticasone propionate in a human bronchial epithelial cell line (Calu-3). J Pharm Sci 2002;91:1561-7.
68. Ehrhardt C, Kneuer C, Laue M, Schaefer UF, Kim KJ, Lehr CM. 16HBE14o-human bronchial epithelial cell layers express P-glycoprotein, lung resistance-related protein, and caveolin-1. Pharm Res 2003;20:545-51.
69. Forbes B, Hashmi N, Martin GP, Lansley AB. Formulation of inhaled medicines: effect of delivery vehicle on immortalized epithelial cells. J Aerosol Med 2000;13:281-8.
70. Lai SK, OHanlon DE, Harrold S, Man ST, Wang YY, Cone R, et al. Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc Natl Acad Sci USA 2007;104:1482-7.
71. Nordgard CT, Draget KI. Oligosaccharides as modulators of rheology in complex mucous systems. Biomacromolecules 2011;12:3084-90.
72. Schuster BS, Suk JS, Woodworth GF, Hanes J. Nanoparticle diffusion in respiratory mucus from humans without lung disease. Biomaterials 2013;34:3439-46.
73. Rubin BK. Physiology of airway mucus clearance. Respir Care 2002;47:761-8.
74. Ruge CA, Kirch J, Lehr CM. Pulmonary drug delivery: from generating aerosols to overcoming biological barriers-therapeutic possibilities and technological challenges. Lancet Respir Med 2013;1:402-13.
75. Sigurdsson HH, Kirch J, Lehr CM. Mucus as a barrier to lipophilic drugs. Int J Pharm 2013;453:56-64.
76. Lillehoj EP, Kato K, Lu W, Kim KC. Cellular and molecular biology of airway mucins. Int Rev Cell Mol Biol 2013;303:139-202.
77. Button B, Cai LH, Ehre C, Kesimer M, Hill DB, Sheehan JK, et al. A periciliary brush promotes the lung health by separating the mucus layer from airway epithelia. Science 2012;337:937-41.
78. Zhu Y, Chidekel A, Shaffer TH. Cultured human airway epithelial cells (calu-3): A model of human respiratory function, structure, and inflammatory responses. Crit Care Res Pract 2010;2010.
79. Seagrave J, Albrecht HH, Hill DB, Rogers DF, Solomon G. Effects of guaifenesin, N-Acetylcysteine, and ambroxol on MUC5AC and mucociliary transport in primary differentiated human trachealbronchial cells. Respir Res 2012;13:98.
80. Kirch J, Schneider A, Abou B, Hopf A, Schaefer UF, Schneider M, et al. Optical tweezers reveal relationship between microstructure and nanoparticle penetration of pulmonary mucus. Proc Natl Acad Sci USA 2012;109:18355-60.
81. Olmsted SS, Padgett JL, Yudin AI, Whaley KJ, Moench TR, Cone RA. Diffusion of macromolecules and virus-like particles in human cervical mucus. Biophys J 2001;81:1930-7.
82. Ludwig A. The use of mucoadhesive polymers in ocular drug delivery. Adv Drug Deliv Rev 2005;57:1595-639.
83. Prego C, Torres D, Alonso MJ. The potential of chitosan for the oral administration of peptides. Expert Opin Drug Deliv 2005;2:843-54.
84. Takeuchi H, Yamamoto H, Kawashima Y. Mucoadhesive nanoparticulate systems for peptide drug delivery. Adv Drug Deliv Rev 2001;47:39-54.
85. Shah PL, Scott SF, Knight RA, Marriott C, Ranasinha C, Hodson ME. In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis. Thorax 1996;51:119-25.
86. Ensign LM, Tang BC, Wang YY, Tse TA, Hoen T, Cone R, et al. Mucus-penetrating nanoparticles for vaginal drug delivery protect against herpes simplex virus. Sci Transl Med 2012;4:138ra79.
87. Cone RA. Barrier properties of mucus. Adv Drug Deliv Rev 2009;61:75-85.
88. Ungaro F, dAngelo I, Coletta C, dEmmanuele di Villa Bianca R, Sorrentino R, Perfetto B, et al. Dry powders based on PLGA nanoparticles for pulmonary delivery of antibiotics: modulation of encapsulation efficiency, release rate and lung deposition pattern by hydrophilic polymers. J Control Release 2012;157:149-59.